Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial
Angela Huttner(University Hospital of Geneva), Veronica Gambillara Fonck(Spital Limmattal), David Scheiner(University Hospital Zurich), Serge De Vallière(Centre Hospitalier Universitaire Vaudois), Patricia Martín(University of California, Los Angeles), Kerstin Kling(Heidelberg University), Stephan Harbarth(University Hospital of Geneva), Rahel Frölich(Spital Limmattal), Jan Poolman(Centre for Research in Early Childhood), Cristina Alaimo(Spital Limmattal), Volker Viereck(University of Göttingen), Germie van den Dobbelsteen(Human Vaccines Project Europe), Gloria Ryu(Kantonsspital Aarau), Todd A. Davies(Janssen (United States)), Tilemachos Kavvadias(University Hospital of Basel), Sabine Gröger(Luzerner Kantonsspital), Darren Abbanat(Johnson & Johnson (United States)), Anita M. Dreyer(Spital Limmattal), Christoph Hatz(Swiss Tropical and Public Health Institute), S Thoelen, Alena Hornacek(Spital Limmattal), Tanja Hülder(Kantonsspital St. Gallen), Ingrid van den Nieuwenhof(Human Vaccines Project Europe), Kellen C. Faé(Max Planck Society), Enos Bernasconi(University of Geneva)
Cited by 209
Related Papers
Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase
|Nature Medicine|2005|1k
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)
|Clinical Microbiology and Infection|2021|1k
Antimicrobial resistance: a global view from the 2013 World Healthcare-Associated Infections Forum
|Antimicrobial Resistance and Infection Control|2013|454
How to use biomarkers of infection or sepsis at the bedside: guide to clinicians
|Intensive Care Medicine|2023|293